MCM
PDLI

MV Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

MV Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,143
Closed -$4K – 386
2017
Q3 		$4K Buy
+1,143
New +$3.18K ﹤0.01% 318

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

MV Capital Management's PDLI Position: Q4 2017 in Review

MV Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2017, closing a stake of 1,143 shares — an estimated $4K sold.

MV Capital Management first reported a position in PDLI in Q3 2017 and held it in 1 quarter. The position peaked at $4K in Q3 2017. 187 funds tracked by Wall St. Rank hold PDLI as of Q4 2017.

  • MV Capital Management reported no remaining PDL BioPharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • MV Capital Management sold 1,143 PDL BioPharma, Inc. shares in Q4 2017, an estimated $4K.
  • MV Capital Management first reported a position in PDL BioPharma, Inc. in Q3 2017 and held it in 1 quarter.
  • MV Capital Management's PDL BioPharma, Inc. position peaked at $4K in Q3 2017.
  • 187 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2017.

Based on MV Capital Management's 13F filing for Q4 2017, filed 5 Mar 2018.